SELLAS Life Sciences Group, Inc.
Complete final data analysis for the Phase 1/2 GPS study
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 12 May 2022
- Due
- 31 Dec 2022
- Delivered
- 10 Nov 2022
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“final data analysis for all evaluable patients expected by the end of 2022”
What we found
Evidence strength A What the grades mean
SELLAS announced final analysis results for the GPS Phase 1/2 ovarian cancer study on November 10, 2022, before the end-of-2022 deadline.
-
A SELLAS Life Sciences Q3 2022 Business Update
“On November 10, 2022, SELLAS announced confirmatory top-line data showing survival and clinical benefits based on the final analysis of the Phase 1/2 clinical trial of GPS in combination with pembrolizumab (Keytruda)” ✓ confirmed on the page
-
B SELLAS Pipeline - Ovarian Cancer
“On November 10, 2022, SELLAS reported final topline clinical data. An analysis of clinical outcomes showed a disease control rate (DCR), the sum of overall response rate and rate of stable disease, of 50.1 percent” ✓ confirmed on the page
-
B SELLAS Q3 2022 Financial Results
“On November 10, 2022, SELLAS announced confirmatory top-line data showing survival and clinical benefits based on the final analysis of the Phase 1/2 clinical trial” ✓ confirmed on the page
Checked 3 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical readout
- Indicative materiality
- Medium rules
- Action
- Complete
- Deliverable
- Phase 1/2 GPS study final data analysis
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- High
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Claude (Anthropic), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Gemini (Google), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you SELLAS Life Sciences Group, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2022-SLS-001996 · Corrections policy